| Nasdaq: AFFX
Affymetrix, Inc. provides life science and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It develops, manufactures and sells products and services for genetic analysis to the genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The company operates through two segments: Affymetrix Core and eBioscience. The Affymetrix Core segment is divided into four business units, namely Expression, Genetic Analysis and Clinical Applications, Life Science Reagents and Corporate. The Expression business unit develops and markets the company's GeneChip gene expression products and services; Genetic Analysis and Clinical Applications business unit develops and markets the company's genotyping, such as the Axiom product line and arrays with clinical research applications, such as the CytoScan cytogenetics arrays; Life Science Reagents business unit develops and sells reagents, enzymes, purification kits and biochemical's used by life science researchers and Corporate business unit is comprised of revenue from royalty arrangements, and field revenue from services provided to customers by the company . The eBioscience segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The company was founded by Stephen P. A. Fodor in 1991 and is headquartered in Santa Clara, CA.